Phase II Trial of Subcutaneous Interferon Followed by Intravenous Hybrid Bolus/Continuous Infusion Interleukin-2 in the Treatment of Renal Cell Carcinoma: Final Results of Cancer Biotherapy Research Group 95-09

2006 ◽  
Vol 21 (2) ◽  
pp. 130-137 ◽  
Author(s):  
Robert O. Dillman ◽  
Michael C. Wiemann ◽  
D. Fritz Tai ◽  
Carol B. DePriest ◽  
Gamini Soori ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Research Group ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Interleukin 2

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.

1998 ◽  
Vol 16 (8) ◽  
pp. 2728-2732 ◽  
Author(s):  
A Ravaud ◽  
B Audhuy ◽  
F Gomez ◽  
B Escudier ◽  
T Lesimple ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Renal Carcinoma ◽  
Phase Ii Trial ◽  
Interleukin 2 ◽  
Interferon Alfa

PURPOSE A phase II trial was designed to determine the efficacy and the tolerance of interleukin-2 (IL-2), interferon alfa-2a (IFNalpha), and fluorouracil (5-FU) in patients with metastatic renal cell carcinoma. PATIENTS AND METHODS One hundred eleven patients were included. Patients received subcutaneous IL-2 9 x 10(6) IU daily for 6 days and IFNalpha 6 x 10(6) IU on days 1, 3, and 5 every other week for 8 weeks. 5-FU was administered through a continuous infusion at 600 mg/m2 for 5 consecutive days for 1 week every 4 weeks. RESULTS The response rate was 1.8% (95% confidence interval [CI], 0% to 4.3%) with only two partial responses (PRs). Toxicity was moderate with 3.6% grade 4 events and two deaths related to treatment. CONCLUSION This regimen of IL-2, IFNalpha, and 5-FU in patients with metastatic renal cell carcinoma was ineffective. The results raise the question of the dose and schedule of subcutaneous cytokines that must be used in metastatic renal carcinoma.

Phase II trial of 5-fluorouracil, interferon-? and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma

Cancer ◽  
1997 ◽  
Vol 80 (11) ◽  
pp. 2128-2132 ◽  
Author(s):  
Julie A. Ellerhorst ◽  
Avishay Sella ◽  
Robert J. Amato ◽  
Shi-Ming Tu ◽  
Randall E. Millikan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Interleukin 2

A Phase II Trial of Continuous-Infusion Recombinant Interleukin-2 in Patients with Advanced Renal Cell Carcinoma

1995 ◽  
Vol 18 (2) ◽  
pp. 104-114 ◽  
Author(s):  
Robert P. Whitehead ◽  
Michael K. Wolf ◽  
Dilip L. Solanki ◽  
George P. Hemstreet ◽  
Pasquale Benedetto ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Interleukin 2 ◽  
Advanced Renal Cell Carcinoma ◽  
Recombinant Interleukin 2

A randomized phase II trial of Interleukin-2 in combination with four different doses of bryostatin in patients with renal cell carcinoma

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4608-4608
Author(s):  
A. C. Peterson ◽  
H. Harlin ◽  
T. Karrison ◽  
J. A. Knost ◽  
J. W. Kugler ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Interleukin 2 ◽  
Randomized Phase Ii ◽  
Different Doses
Sign in / Sign up

Export Citation Format

Share Document